At that time, plerixafor, a small-molecule bicyclam CXCR4 antagonist, was the only CXCR4 inhibitor approved by the FDA in association with G-CSF for autologous stem cell mobilization in patients with non-Hodgkin’s lymphoma and multiple myeloma (MM) [78,79]. The gene discussed is CSF3; the disease is AL amyloidosis.